Ventas, Inc.

VTR

US92276F1003

Ventas, Inc. specializes in owning and managing healthcare and medical-residential facilities. At the end of 2022, the group's portfolio included 1,237 assets consisting primarily of senior housing (802), medical office buildings (313), rehabilitation and long-term acute care facilities (36), laboratories and research facilities (32), skilled nursing facilities (16), medical and surgical facilities (13). Net sales are distributed geographically as follows: the United States (88.5%), Canada (10.9%) and the United Kingdom (0.6%).

Sector

Specialized REITs

Calendar

2024-06-30 - Détachement de

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Ventas ramps up acquisitions in property for senior citizens : Ventas CEO

March 08, 2024 at 03:32 pm

More Strategies

Ratings for Ventas, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

50.69 USD

Average target price

54.56 USD

Spread / Average Target

+7.63%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Healthcare REITs

	1st Jan change	Capi.
VENTAS, INC.	+1.71%	20.48B
WELLTOWER INC.	+14.20%	61.57B
HEALTHPEAK PROPERTIES, INC.	-0.76%	13.83B
OMEGA HEALTHCARE INVESTORS, INC.	+9.59%	8.3B
HEALTHCARE REALTY TRUST INCORPORATED	-5.86%	6.19B
CARETRUST REIT, INC.	+11.89%	3.62B
SABRA HEALTH CARE REIT, INC.	+4.84%	3.46B
AEDIFICA SA	-8.64%	2.97B
NATIONAL HEALTH INVESTORS, INC.	+20.54%	2.92B
COFINIMMO	-18.84%	2.37B

Healthcare REITs

Market Closed - Nyse Other stock markets 16:00:01 2024-06-24 EDT			5-day change	1st Jan Change
50.69 ^USD	+0.54%		+1.38%	+1.71%

06-21	Raymond James Adjusts Price Target on Ventas to $55 From $50.26	MT
06-20	BNP Paribas Exane Adjusts Price Target on Ventas to $59 From $54	MT

Raymond James Adjusts Price Target on Ventas to $55 From $50.26	06-21	MT
BNP Paribas Exane Adjusts Price Target on Ventas to $59 From $54	06-20	MT
Baird Adjusts Price Target on Ventas to $51 From $49	06-14	MT
BMO Capital Adjusts Price Target on Ventas to $57 From $53, Keeps Outperform Rating	06-13	MT
Scotiabank Adjusts Price Target on Ventas to $52 From $51	06-12	MT
Evercore ISI Adjusts Price Target on Ventas to $53 From $51, Keeps Outperform Rating	06-10	MT
Transcript : Ventas, Inc. Presents at Nareit REIT Week: 2024 Investor Conference, Jun-04-2024 02:15 PM	06-04
Deutsche Bank Adjusts Ventas Price Target to $55 From $60, Maintains Buy Rating	06-03	MT
Wells Fargo Adjusts Price Target on Ventas to $49 From $46	05-30	MT
JPMorgan Adjusts Price Target on Ventas to $50 From $48	05-29	MT
BMO Capital Adjusts Ventas Price Target to $53 From $51	05-20	MT
Scotiabank Adjusts Price Target on Ventas to $51 From $47	05-16	MT
Morgan Stanley Adjusts Price Target on Ventas to $49 From $47, Keeps Equalweight Rating	05-16	MT
Ventas Maintains Quarterly Dividend at $0.45 per Share; Payable July 18 to Shareholders of Record on July 1	05-15	MT
Ventas, Inc. Declares Second Quarter 2024 Dividend, Payable on July 18, 2024	05-14	CI
Ventas Insider Sold Shares Worth $697,653, According to a Recent SEC Filing	05-13	MT
Jefferies Adjusts Price Target on Ventas to $56 From $52	05-10	MT
Ventas Unit Prices $500 Million Debt Offering	05-09	MT
RBC Capital Adjusts Price Target on Ventas to $52 From $50	05-07	MT
ANALYST RECOMMENDATIONS : Nvidia, The Home Depot, Lowe's, Rollins...	05-07
Evercore ISI Adjusts Ventas' Price Target to $51 From $50, Keeps Outperform Rating	05-07	MT
Wedbush Raises Price Target on Ventas to $54 Form $52, Keeps Outperform Rating	05-03	MT
Transcript : Ventas, Inc., Q1 2024 Earnings Call, May 02, 2024	05-02
Evercore ISI Adjusts Price Target on Ventas to $50 From $49	05-02	MT
Ventas lifts lower-end of annual FFO forecast on strong quarterly demand	05-01	RE